Impact of IL-1 inhibition on fatigue associated with autoinflammatory syndromes

References

• Kuemmerle-Deschner JB, Haug I. Canakinumab in patients with cryopyrin-associated periodic syndrome: an update for clinicians. Ther Adv Musculoskelet Dis. 2013;5(6):315–29.
   PubMedGoogle Scholar
• Cuisset L, Jeru I, Dumont B, Fabre A, Cochet E, Le Bozec J, et al. Mutations in the autoinflammatory cryopyrin-associated periodic syndrome gene: epidemiological study and lessons from eight years of genetic analysis in France. Ann Rheum Dis. 2011;70(3):495–9.
   PubMed Web of Science ®Google Scholar
• Aksentijevich I, C DP, Remmers EF, Mueller JL, Le J, Kolodner RD, et al. The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum. 2007;56(4):1273–85.
   PubMed Web of Science ®Google Scholar
• Farasat S, Aksentijevich I, Toro JR. Autoinflammatory diseases: clinical and genetic advances. Arch Dermatol. 2008;144(3):392–402.
   PubMed Web of Science ®Google Scholar
• Touitou I, Kone-Paut I. Autoinflammatory diseases. Best Pract Res Clin Rheumatol. 2008;22(5):811–29.
   PubMed Web of Science ®Google Scholar
• Marsaud C, Marie I, Koné-Paut I. P02–027 - Quality of life in CAPS treated by Canakinumab. Pediatric Rheumatol Online J. 2013;11(Suppl 1):A134.
   Google Scholar
• Stych B, Dobrovolny D. Familial cold auto-inflammatory syndrome (FCAS): characterization of symptomatology and impact on patients’ lives. Curr Med Res Opin. 2008;24(6):1577–82.
   PubMed Web of Science ®Google Scholar
• Davis JM, Bailey SP. Possible mechanisms of central nervous system fatigue during exercise. Med Sci Sports Exerc. 1997;29(1):45–57.
   PubMed Web of Science ®Google Scholar
• Davis JM, Alderson NL, Welsh RS. Serotonin and central nervous system fatigue: nutritional considerations. Am J Clin Nutr. 2000;72(2 Suppl):573S–8S.
   PubMed Web of Science ®Google Scholar
• Norheim KB, Jonsson G, Omdal R. Biological mechanisms of chronic fatigue. Rheumatology (Oxford). 2011;50(6):1009–18.
   PubMed Web of Science ®Google Scholar
• Kuno K, Matsushima K. The IL-1 receptor signaling pathway. J Leukoc Biol. 1994;56(5):542–7.
   PubMed Web of Science ®Google Scholar
• Bluthe RM, Beaudu C, Kelley KW, Dantzer R. Differential effects of IL-1ra on sickness behavior and weight loss induced by IL-1 in rats. Brain Res. 1995;677(1):171–6.
   PubMed Web of Science ®Google Scholar
• Rinehart J, Hersh E, Issell B, Triozzi P, Buhles W, Neidhart J. Phase 1 trial of recombinant human interleukin-1 beta (rhIL-1 beta), carboplatin, and etoposide in patients with solid cancers: Southwest Oncology, Group Study 8940. Cancer Invest. 1997;15(5):403–10.
   PubMed Web of Science ®Google Scholar
• Hoffman HM, Rosengren S, Boyle DL, Cho JY, Nayar J, Mueller JL, et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet. 2004;364(9447):1779–85.
   PubMed Web of Science ®Google Scholar
• Omdal R, Gunnarsson R. The effect of interleukin-1 blockade on fatigue in rheumatoid arthritis–a pilot study. Rheumatol Int. 2005;25(6):481–4.
   PubMed Web of Science ®Google Scholar
• Cleare AJ. The neuroendocrinology of chronic fatigue syndrome. Endocr Rev. 2003;24(2):236–52.
   PubMed Web of Science ®Google Scholar
• Ramamoorthy S, Ramamoorthy JD, Prasad PD, Bhat GK, Mahesh VB, Leibach FH, et al. Regulation of the human serotonin transporter by interleukin-1 beta. Biochem Biophys Res Commun. 1995;216(2):560–7.
   PubMed Web of Science ®Google Scholar
• Mossner R, Heils A, Stober G, Okladnova O, Daniel S, Lesch KP. Enhancement of serotonin transporter function by tumor necrosis factor alpha but not by interleukin-6. Neurochem Int. 1998;33(3):251–4.
   PubMed Web of Science ®Google Scholar
• Morikawa O, Sakai N, Obara H, Saito N. Effects of interferon-alpha, interferon-gamma and cAMP on the transcriptional regulation of the serotonin transporter. Eur J Pharmacol. 1998;349(2–3):317–24.
   PubMed Web of Science ®Google Scholar
• Wichers MC, Maes M. The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression. J Psychiatry Neurosci. 2004;29(1):11–7.
   PubMed Web of Science ®Google Scholar
• Morris G, Berk M, Galecki P, Walder K, Maes M. The neuro-immune pathophysiology of central and peripheral fatigue in systemic immune-inflammatory and neuro-immune diseases. Mol Neurobiol. 2015. [Epub ahead of print]
   Google Scholar
• Aksentijevich I, Nowak M, Mallah M, Chae JJ, Watford WT, Hofmann SR, et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum. 2002;46(12):3340–8.
   PubMed Web of Science ®Google Scholar
• Goldbach-Mansky R. Current status of understanding the pathogenesis and management of patients with NOMID/CINCA. Curr Rheumatol Rep. 2011;13(2):123–31.
   PubMed Web of Science ®Google Scholar
• Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet. 2001;29(3):301–5.
   PubMed Web of Science ®Google Scholar
• Hoffman DHM. Familial cold autoinflammatory syndrome. J Allergy Clin Immunol. 2001;108(4):615–20.
   PubMed Web of Science ®Google Scholar
• Kuemmerle-Deschner JB, Lohse P, Koetter I, Dannecker GE, Reess F, Ummenhofer K, et al. NLRP3 E311K mutation in a large family with Muckle-Wells syndrome - description of a heterogeneous phenotype and response to treatment. Arthritis Res Ther. 2011;13(6):R196.
   PubMed Web of Science ®Google Scholar
• Goldbach-Mansky R, Dailey NJ, Canna SW, Gelabert A, Jones J, Rubin BI, et al. Neonatal-Onset Multisystem Inflammatory Disease Responsive to Interleukin-1β Inhibition. N Engl J Med. 2006;355(6):581–92.
   PubMed Web of Science ®Google Scholar
• Ye Z, Ting JP. NLR, the nucleotide-binding domain leucine-rich repeat containing gene family. Curr Opin Immunol. 2008;20(1):3–9.
   PubMed Web of Science ®Google Scholar
• Petrilli V, Dostert C, Muruve DA, Tschopp J. The inflammasome: a danger sensing complex triggering innate immunity. Curr Opin Immunol. 2007;19(6):615–22.
   PubMed Web of Science ®Google Scholar
• Arostegui JI.Pathophysiological mechanisms underlying cryopyrin-associated periodic syndromes: genetic and molecular basis and the inflammasome. Med Clin (Barc). 2011;136 Suppl 1:22–8.
   PubMedGoogle Scholar
• Kone-Paut I, Lachmann HJ, Kuemmerle-Deschner JB, Hachulla E, Leslie KS, Mouy R, et al. Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study. Arthritis Res Ther. 2011;13(6):R202.
   PubMed Web of Science ®Google Scholar
• Hewlett S, Dures E, Almeida C. Measures of fatigue: Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional Questionnaire (BRAF MDQ), Bristol Rheumatoid Arthritis Fatigue Numerical Rating Scales (BRAF NRS) for severity, effect, and coping, Chalder Fatigue Questionnaire (CFQ), Checklist Individual Strength (CIS20R and CIS8R), Fatigue Severity Scale (FSS), Functional Assessment Chronic Illness Therapy (Fatigue) (FACIT-F), Multi-Dimensional Assessment of Fatigue (MAF), Multi-Dimensional Fatigue Inventory (MFI), Pediatric Quality Of Life (PedsQL) Multi-Dimensional Fatigue Scale, Profile of Fatigue (ProF), Short Form 36 Vitality Subscale (SF-36 VT), and Visual Analog Scales (VAS). Arthritis Care Res (Hoboken). 2011;63 Suppl 11:S263–86.
   PubMed Web of Science ®Google Scholar
• Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med. 2009;360(23):2416–25.
   PubMed Web of Science ®Google Scholar
• Kuemmerle-Deschner JB, Ramos E, Blank N, Roesler J, Felix SD, Jung T, et al. Canakinumab (ACZ885, a fully human IgG1 anti-IL-1beta mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS). Arthritis Res Ther. 2011;13(1):R34.
   PubMed Web of Science ®Google Scholar
• Hoffman HM, Throne ML, Amar NJ, Sebai M, Kivitz AJ, Kavanaugh A, et al. Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes: Results from two sequential placebo-controlled studies. Arthritis Rheum. 2008;58(8):2443–52.
   PubMed Web of Science ®Google Scholar
• Goldbach-Mansky R, Shroff S, Wilson M, Snyder C, Plehn S, Barham B, et al. A Pilot Study to Evaluate the Safety and Efficacy of the Long-acting IL-1 Inhibitor, Rilonacept (IL-1 Trap) in Patients with Familial Cold Autoinflammatory Syndrome (FCAS). Arthritis Rheum. 2008;58(8):2432–42.
   PubMed Web of Science ®Google Scholar
• Sibley CH, Plass N, Snow J, Wiggs EA, Brewer CC, King KA, et al. Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes. Arthritis Rheum. 2012;64(7):2375–86.
   PubMed Web of Science ®Google Scholar
• Toker O, Hashkes PJ. Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS). Biologics. 2010;4:131–8.
   PubMedGoogle Scholar
• Patarca R, Klimas NG, Lugtendorf S, Antoni M, Fletcher MA. Dysregulated expression of tumor necrosis factor in chronic fatigue syndrome: interrelations with cellular sources and patterns of soluble immune mediator expression. Clin Infect Dis. 1994;18 Suppl 1:S147–53.
   PubMed Web of Science ®Google Scholar
• Kontzias A, Efthimiou P. The use of Canakinumab, a novel IL-1beta long-acting inhibitor, in refractory adult-onset Still's disease. Semin Arthritis Rheum. 2012;42(2):201–5.
   PubMed Web of Science ®Google Scholar